- Home
- TSAT vs CTMX Comparison
TSAT vs CTMX Comparison
Compare TSAT & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSAT
- CTMX
- Stock Information
- Founded
- TSAT 1969
- CTMX 2008
- Country
- TSAT Canada
- CTMX United States
- Employees
- TSAT N/A
- CTMX N/A
- Industry
- TSAT Metal Fabrications
- CTMX Biotechnology: Pharmaceutical Preparations
- Sector
- TSAT Industrials
- CTMX Health Care
- Exchange
- TSAT Nasdaq
- CTMX Nasdaq
- Market Cap
- TSAT 394.3M
- CTMX 380.9M
- IPO Year
- TSAT 1996
- CTMX 2015
- Fundamental
- Price
- TSAT $20.28
- CTMX $2.14
- Analyst Decision
- TSAT
- CTMX Strong Buy
- Analyst Count
- TSAT 0
- CTMX 3
- Target Price
- TSAT N/A
- CTMX $5.67
- AVG Volume (30 Days)
- TSAT 95.6K
- CTMX 3.9M
- Earning Date
- TSAT 08-06-2025
- CTMX 08-07-2025
- Dividend Yield
- TSAT N/A
- CTMX N/A
- EPS Growth
- TSAT N/A
- CTMX 263.20
- EPS
- TSAT N/A
- CTMX 0.49
- Revenue
- TSAT $358,754,564.00
- CTMX $141,100,000.00
- Revenue This Year
- TSAT N/A
- CTMX N/A
- Revenue Next Year
- TSAT N/A
- CTMX N/A
- P/E Ratio
- TSAT N/A
- CTMX $4.24
- Revenue Growth
- TSAT N/A
- CTMX 18.01
- 52 Week Low
- TSAT $9.85
- CTMX $0.40
- 52 Week High
- TSAT $29.91
- CTMX $3.10
- Technical
- Relative Strength Index (RSI)
- TSAT 38.57
- CTMX 50.30
- Support Level
- TSAT $20.12
- CTMX $1.89
- Resistance Level
- TSAT $21.27
- CTMX $2.22
- Average True Range (ATR)
- TSAT 0.96
- CTMX 0.18
- MACD
- TSAT -0.14
- CTMX 0.02
- Stochastic Oscillator
- TSAT 21.22
- CTMX 58.62
About TSAT Telesat Corporation and Class B Variable Voting Shares
Telesat Corp is a satellite operator, that provides its customers with mission-critical communications services. It operates in a single operating segment, in which it provides satellite-based services to its broadcast, enterprise, and consulting customers around the world. Geographically, it derives a majority of its revenue from Canada. It derives revenue from Broadcast, Enterprise, Consulting, and others.
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.